23rd Mar 2016 07:37
LONDON (Alliance News) - Pharmaceuticals company AstraZeneca PLC on Wednesday said its Brilinta drug missed its primary efficacy endpoint in trials treating strokes.
The company said the primary endpoint goal of time to first occurrence of any event from a stroke, heart attack or death was not met by the treatment.
Fewer events were observed in the Brilinta treatment against the comparison, but the trend was not statistically significant, AstraZeneca said.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
Astrazeneca